Crossmark

Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)

Crossref DOI link: https://doi.org/10.1016/j.anpede.2023.09.006

Published Print: 2023-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Francisco, Laura

Cruz-Cañete, Marta

Pérez, Carlos

Couceiro, José Antonio

Otheo, Enrique

Launes, Cristian

Rodrigo, Carlos

Jiménez, Ana Belén

Llorente, Marta

Montesdeoca, Abián

Rumbao, José

Calvo, Cristina

Frago, Susana

Tagarro, Alfredo
License Information

Text and Data Mining valid from 2023-10-01

Version of Record valid from 2023-09-18
More Information

This article is maintained by: Elsevier

Article Title: Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)

Journal Title: Anales de Pediatría (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.anpede.2023.09.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.anpedi.2023.09.006

Content Type: article

Copyright: © 2023 Asociación Española de Pediatría. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below